Background: Low docosahexaenoic acid (DHA) plasma concentration was reported in CF patients. Arachidonic acid (AA) is associated with increased proinflammatory eicosanoids, whereas DHA provides antinflammatory products. Aims: To evaluate biochemical and clinical effects of one year DHA supplementation in CF patients. Methods: A multicenter double-blind placebo-controlled study was performed. Thirty-four CF patients aged 6 to 10 years were randomized to receive DHA (100 mg/kg/die in the first month and 1 g per day thereafter) or placebo (germ oil in identical capsules). Plasma fatty acids concentrations were determined by GLC. Clinical (pulmonary function and anthropometry) and biochemical data (standard biochemistry, inflammatory cytokines, liposoluble vitamins, steatocrit) were collected every 6 months. Results: Five patients dropped-out. In the treatment group, but not in the control group, a significant DHA enrichment in plasma (median % of plasma FA from 1.40 up to 4.5%) and a decrease in AA/DHA ratio were documented after 6 months. Interleukin-8 decreased significantly after 6 months but this finding was not consistently maintained. No changes in respiratory function, nutritional status and other biochemical parameters were detected in both groups. Conclusions: DHA supplementation for one year did not induce any relevant improvement in CF patients. Results: 49 patients were included. The median age of HEN support was 3.16 years (y) (IQR 0.74−9.7). The first enteral access was the nasogastric tube (NGT) in 49% of the children followed by gastrostomy (G, 42.9%). Children with NGT were significant younger at the beginning of HEN than patients with G (p = 0.01). 85.7% of the children used enteral nutrition pumps. The cyclic administration method was the most frequent (65.3%). Homemade food was used in 14.3% of the patients with G and in 5.3% of the cases with NGT (c 2 , p < 0.001). Enteral formulas were used in 91.8% of the patients, only 11% of patients received enteral formula and homemade foods; the most common formula (30.6%) was paediatric polymeric followed by adult formula. Nutritional support concluded in 61.2% of the patients [median 1.03 y (IQR 0.13-2.30)], in 60% of the cases the cessation was because transition to oral feeding. The mean duration of HEN was significantly higher in patients with G versus NGT carriers (p = 0.0001). Conclusion: CF patientsrequiring nutritional support are clearly divided into 2 populations: younger patients tend to use NGT for a short period of time and in older patients the G is often used for more prolonged periods of time. The cyclic administration method is the most frequent used in these patients in order to preserve the oral feeding. Most patients used enteral formulas. Objective: In clinical practice, the need often arises to administer CREON (capsules containing pancreatin gastro-resistant pellets) by G-tube. Our aim was to identify G-tubes that allow administration of CREON pellets without clogging, sticking, pellet damage, or loss of integrity. Methods: In this in vitro study, CREON capsules were opened, pellets sprinkled onto baby food pH <4.5 (applesauce and bananas of 2 different brands), stirred gently, then using a syringe pushed slowly (~15 cc in 10−15 s) through G-tubes of different types/sizes. G-tubes were visually inspected for clogging, sticking, and pellet damage. If there was none with all 4 foods, pellet integrity (gastric resistance, lipase activity) was tested by an in vitro dissolution method modified from USP and PhEur monographs (2-h gastric simulation step). Integrity was considered maintained at 80% actual lipase activity per capsule at end of this step.
Results: There was no clogging, sticking, or visible pellet damage, and integrity was maintained when administering CREON through these G-tubes: 
